Today, the FDA posted four warning letters to companies for introducing unapproved GLP-1s, including semaglutide, tirzepatide and/or retatrutide products into interstate commerce. The letters were sent to:  Xcel Peptides  Swisschems Summit Research  Prime Peptides The agency also sent a warning letter to Veronvy, which offers unapproved and misbranded oral GLP-1  products, including one that claims to be approved by FDA.